Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMRA NASDAQ:HROW NASDAQ:OVID NASDAQ:PGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMRADamora Therapeutics, Inc. Common Stock$23.22-4.7%$26.02$2.45▼$38.33$1.40B1.5250,552 shs143,391 shsHROWHarrow$30.35-20.2%$37.81$24.62▼$54.85$1.13B0.34706,369 shs3.15 million shsOVIDOvid Therapeutics$2.79-0.2%$2.41$0.27▼$3.11$367.29M0.182.62 million shs745,307 shsPGENPrecigen$4.06-3.5%$3.79$1.26▼$5.47$1.45B1.074.20 million shs986,887 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMRADamora Therapeutics, Inc. Common Stock+0.83%-3.94%-5.65%+13.20%+789.05%HROWHarrow-0.50%-6.99%+5.87%-20.27%+55.90%OVIDOvid Therapeutics-0.36%0.00%+1.45%+70.12%+861.74%PGENPrecigen-0.24%+2.94%+0.96%-9.87%+215.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMRADamora Therapeutics, Inc. Common Stock$23.22-4.7%$26.02$2.45▼$38.33$1.40B1.5250,552 shs143,391 shsHROWHarrow$30.35-20.2%$37.81$24.62▼$54.85$1.13B0.34706,369 shs3.15 million shsOVIDOvid Therapeutics$2.79-0.2%$2.41$0.27▼$3.11$367.29M0.182.62 million shs745,307 shsPGENPrecigen$4.06-3.5%$3.79$1.26▼$5.47$1.45B1.074.20 million shs986,887 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMRADamora Therapeutics, Inc. Common Stock+0.83%-3.94%-5.65%+13.20%+789.05%HROWHarrow-0.50%-6.99%+5.87%-20.27%+55.90%OVIDOvid Therapeutics-0.36%0.00%+1.45%+70.12%+861.74%PGENPrecigen-0.24%+2.94%+0.96%-9.87%+215.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMRADamora Therapeutics, Inc. Common Stock 2.88Moderate Buy$43.4086.91% UpsideHROWHarrow 2.64Moderate Buy$69.86130.15% UpsideOVIDOvid Therapeutics 2.89Moderate Buy$4.6366.07% UpsidePGENPrecigen 2.43Hold$9.50134.28% UpsideCurrent Analyst Ratings BreakdownLatest OVID, DMRA, PGEN, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026DMRADamora Therapeutics, Inc. Common Stock Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$40.004/23/2026DMRADamora Therapeutics, Inc. Common Stock Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy4/22/2026HROWHarrow Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026OVIDOvid Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PGENPrecigen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.004/15/2026OVIDOvid Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.004/9/2026OVIDOvid Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $4.004/7/2026HROWHarrow B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$74.00 ➝ $65.004/3/2026HROWHarrow Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/26/2026OVIDOvid Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/A($110.11) per shareN/AHROWHarrow$272.30M4.15$0.69 per share44.23$1.41 per share21.53OVIDOvid Therapeutics$7.25M50.66N/AN/A$1.00 per share2.79PGENPrecigen$9.68M149.34N/AN/A$0.06 per share67.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMRADamora Therapeutics, Inc. Common Stock-$209.84M-$12.10N/AN/AN/AN/A-147.05%-279.49%N/AHROWHarrow-$5.14M-$0.17N/A12.29N/A-1.89%36.51%5.06%N/AOVIDOvid Therapeutics-$17.41M-$0.31N/AN/AN/A-240.11%-23.98%-18.63%5/12/2026 (Estimated)PGENPrecigen-$250.64M-$1.34N/A14.48N/A-2,588.21%2,317.96%49.65%5/13/2026 (Estimated)Latest OVID, DMRA, PGEN, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026PGENPrecigen-$0.03N/AN/AN/A$20.81 millionN/A5/12/2026Q1 2026OVIDOvid Therapeutics-$0.12-$0.12N/A-$0.12$0.06 millionN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million3/25/2026Q4 2025PGENPrecigen-$0.10-$0.01+$0.09-$0.01$8.29 million$4.57 million3/18/2026Q4 2025OVIDOvid Therapeutics-$0.10$0.06+$0.16$0.06$0.06 million$0.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMRADamora Therapeutics, Inc. Common StockN/A12.9812.98HROWHarrow4.672.202.06OVIDOvid Therapeutics0.098.978.97PGENPrecigen4.463.092.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMRADamora Therapeutics, Inc. Common Stock14.20%HROWHarrow72.76%OVIDOvid Therapeutics72.24%PGENPrecigen33.51%Insider OwnershipCompanyInsider OwnershipDMRADamora Therapeutics, Inc. Common Stock0.40%HROWHarrow12.80%OVIDOvid Therapeutics13.10%PGENPrecigen47.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMRADamora Therapeutics, Inc. Common Stock4060.30 million60.06 millionNo DataHROWHarrow18037.27 million32.50 millionOptionableOVIDOvid Therapeutics60131.88 million114.60 millionOptionablePGENPrecigen190356.51 million188.59 millionOptionableOVID, DMRA, PGEN, and HROW HeadlinesRecent News About These CompaniesPrecigen (PGEN) Expected to Announce Quarterly Earnings on WednesdayMay 11 at 5:28 AM | americanbankingnews.comPrecigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13May 7, 2026 | prnewswire.comPrecigen (PGEN) to Release Earnings on WednesdayMay 6, 2026 | marketbeat.comPrecigen (NASDAQ:PGEN) Stock Crosses Below 200 Day Moving Average - Here's WhyMay 5, 2026 | marketbeat.comIs Precigen, Inc. (PGEN) A Good Stock To Buy Now?May 3, 2026 | finance.yahoo.comIs Precigen, Inc. (PGEN) A Good Stock To Buy Now?May 3, 2026 | insidermonkey.comComparing Precigen (NASDAQ:PGEN) & ALX Oncology (NASDAQ:ALXO)May 2, 2026 | americanbankingnews.comAnalysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $9.50May 1, 2026 | americanbankingnews.comPrecigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of "Hold" by AnalystsApril 26, 2026 | marketbeat.comPrecigen (NASDAQ:PGEN) Trading Up 7.5% - Still a Buy?April 20, 2026 | marketbeat.comIs Precigen Inc. (PGEN) The Best Healthcare Penny Stock to Buy?April 15, 2026 | finance.yahoo.comPrecigen (NASDAQ:PGEN) Trading Down 5.6% - Here's WhyApril 14, 2026 | marketbeat.comWall Street bullish on Precigen (PGEN) as the company transitions to commercial stageApril 12, 2026 | msn.comPrecigen (PGEN) price target increased by 11.76% to 9.69April 9, 2026 | msn.comPrecigen sees Q1 revenue exceeding $18M, consensus $20.8MApril 8, 2026 | finance.yahoo.comPrecigen, Inc: Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 MillionApril 7, 2026 | finanznachrichten.dePrecigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 MillionApril 7, 2026 | finance.yahoo.comPrecigen, Inc. (PGEN) Poised for Growth on Respiratory Papillomatosis Treatment ProspectsApril 6, 2026 | insidermonkey.comPrecigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP TranscriptApril 1, 2026 | seekingalpha.comPrecigen to Participate in a Fireside Chat with H.C. Wainwright on March 31March 30, 2026 | prnewswire.comIs It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?March 27, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGPU Prices Are Surging—3 Ways to Play the AI Chip ShortageBy Thomas Hughes | April 14, 20263 Space ETFs to Pick Up Before SpaceX IPOBy Nathan Reiff | April 19, 2026The New Nokia: A Bullish Upgrade Ignites This Big AI Bet By Jeffrey Neal Johnson | April 16, 2026Is Oracle Undervalued as Cloud Growth Accelerates?By Thomas Hughes | April 29, 2026Is Backblaze the Next Momentum Monster?By Jeffrey Neal Johnson | May 7, 2026OVID, DMRA, PGEN, and HROW Company DescriptionsDamora Therapeutics, Inc. Common Stock NASDAQ:DMRA$23.22 -1.14 (-4.68%) As of 11:39 AM EasternGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Harrow NASDAQ:HROW$30.35 -7.69 (-20.21%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Ovid Therapeutics NASDAQ:OVID$2.78 -0.01 (-0.18%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Precigen NASDAQ:PGEN$4.06 -0.15 (-3.45%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
